02:30:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2022-02-23 08:45:00

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today changes to its commercial organization. Jesper Floyd Kristiansen, currently VP Business Development Europe will take over additional responsibilities and change his title to VP Global Business Development. A new Director of Marketing Communications, Mark Gray, will join the company on March 1st. Pia van der Zee, currently VP Marketing, has accepted a position outside of 2cureX and will leave the company mid-March.

The distribution network was expanded in 2021, and further strengthened in 2022 and consequently management has decided to strengthen the distributor support activities by rearranging the commercial organization.

The Marketing function has until now been covering the support to the growing IndiTreat® commercial network and at the same time the communications activities organized in two working streams. These activities will now be redistributed.

Distribution Related activities are grouped together

All activities related to distributor support will become part of the Business Development department, led by Jesper Floyd Kristiansen, whose title going forward will be VP Global Business Development. With this change the company seeks to group all distributor-related activities under one head, to strengthen alignment and continuity.

Appointing a new Director of Marketing Communications
For the Marketing Communications activities, a new Director, Marketing Communications will join 2cureX on March 1st. Mark Gray is a communications professional with a long experience in the In Vitro Diagnostics industry, where he has developed his career in leading companies like Sysmex Europe.

Pia van der Zee who was holding the role of VP Marketing, has decided to pursue an opportunity outside of 2cureX and will leave the company in mid-March. Pia has played an important role leading marketing projects in the last months, and the company wants to recognize her contribution and wish her all kinds of success in her new position.

With the announced changes 2cureX is adapting the organizational structure to the evolving needs as it is rolling out its commercialization roadmap.